|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZCCHC12 |
Gene summary for ZCCHC12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZCCHC12 | Gene ID | 170261 |
| Gene name | zinc finger CCHC-type containing 12 | |
| Gene Alias | PNMA7A | |
| Cytomap | Xq24 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6PEW1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 170261 | ZCCHC12 | PTCwithHT_1 | Human | Thyroid | HT | 2.30e-02 | 5.36e-01 | 0.0238 |
| 170261 | ZCCHC12 | PTCwithHT_8 | Human | Thyroid | HT | 5.27e-10 | 7.11e-01 | 0.0351 |
| 170261 | ZCCHC12 | PTCwithoutHT_4_2 | Human | Thyroid | PTC | 6.90e-05 | 8.01e-01 | 0.0455 |
| 170261 | ZCCHC12 | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.88e-19 | 1.24e+00 | 0.0381 |
| 170261 | ZCCHC12 | male-WTA | Human | Thyroid | PTC | 1.22e-43 | 8.02e-01 | 0.1037 |
| 170261 | ZCCHC12 | female-WTA | Human | Thyroid | PTC | 4.89e-15 | 8.57e-01 | 0.0726 |
| 170261 | ZCCHC12 | PTC01 | Human | Thyroid | PTC | 3.39e-79 | 3.22e+00 | 0.1899 |
| 170261 | ZCCHC12 | PTC04 | Human | Thyroid | PTC | 1.48e-61 | 2.82e+00 | 0.1927 |
| 170261 | ZCCHC12 | PTC05 | Human | Thyroid | PTC | 1.73e-18 | 1.19e+00 | 0.2065 |
| 170261 | ZCCHC12 | PTC06 | Human | Thyroid | PTC | 1.10e-50 | 2.37e+00 | 0.2057 |
| 170261 | ZCCHC12 | PTC07 | Human | Thyroid | PTC | 6.84e-92 | 3.06e+00 | 0.2044 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZCCHC12 | SNV | Missense_Mutation | novel | c.235N>A | p.Glu79Lys | p.E79K | Q6PEW1 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
| ZCCHC12 | SNV | Missense_Mutation | c.30N>G | p.Asn10Lys | p.N10K | Q6PEW1 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD | |
| ZCCHC12 | SNV | Missense_Mutation | c.829G>A | p.Val277Met | p.V277M | Q6PEW1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| ZCCHC12 | SNV | Missense_Mutation | novel | c.1087N>C | p.Glu363Gln | p.E363Q | Q6PEW1 | protein_coding | deleterious_low_confidence(0.02) | benign(0.275) | TCGA-E2-A1LI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ZCCHC12 | insertion | In_Frame_Ins | novel | c.1023_1024insGCCATGAAATTGGTGTTTGGGGAGTCTGAAAGCAGTGTG | p.Arg341_Lys342insAlaMetLysLeuValPheGlyGluSerGluSerSerVal | p.R341_K342insAMKLVFGESESSV | Q6PEW1 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ZCCHC12 | deletion | Frame_Shift_Del | novel | c.12_19delNNNNNNNN | p.Ile4MetfsTer4 | p.I4Mfs*4 | Q6PEW1 | protein_coding | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| ZCCHC12 | SNV | Missense_Mutation | c.351N>A | p.Met117Ile | p.M117I | Q6PEW1 | protein_coding | deleterious(0.03) | probably_damaging(0.943) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZCCHC12 | SNV | Missense_Mutation | novel | c.549N>C | p.Glu183Asp | p.E183D | Q6PEW1 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZCCHC12 | SNV | Missense_Mutation | c.308N>T | p.Ala103Val | p.A103V | Q6PEW1 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AA-3667-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZCCHC12 | SNV | Missense_Mutation | novel | c.692N>A | p.Arg231His | p.R231H | Q6PEW1 | protein_coding | deleterious(0.02) | possibly_damaging(0.799) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |